Premium
Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation
Author(s) -
Weber Brittany,
He Zeling,
Yang Nicole,
Playford Martin P.,
Weisenfeld Dana,
Iannaccone Christine,
Coblyn Jonathan,
Weinblatt Michael,
Shadick Nancy,
Di Carli Marcelo,
Mehta Nehal N.,
Plutzky Jorge,
Liao Katherine P.
Publication year - 2021
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41613
Subject(s) - medicine , rheumatoid arthritis , inflammation , cohort , c reactive protein , gastroenterology , biomarker , liter , prospective cohort study , arthritis , endocrinology , biochemistry , chemistry
Objective Patients with rheumatoid arthritis (RA) are 1.5 times more likely to develop cardiovascular disease (CVD) attributed to chronic inflammation. A decrease in inflammation in patients with RA is associated with increased low‐density lipoprotein (LDL) cholesterol. This study was undertaken to prospectively evaluate the changes in lipid levels among RA patients experiencing changes in inflammation and determine the association with concomitant temporal patterns in markers of myocardial injury. Methods A total of 196 patients were evaluated in a longitudinal RA cohort, with blood samples and high‐sensitivity C‐reactive protein (hsCRP) levels measured annually. Patients were stratified based on whether they experienced either a significant increase in inflammation (an increase in hsCRP of ≥10 mg/liter between any 2 time points 1 year apart; designated the increased inflammation cohort [n = 103]) or decrease in inflammation (a decrease in hsCRP of ≥10 mg/liter between any 2 time points 1 year apart; designated the decreased inflammation cohort [n = 93]). Routine and advanced lipids, markers of inflammation (interleukin‐6, hsCRP, soluble tumor necrosis factor receptor II), and markers of subclinical myocardial injury (high‐sensitivity cardiac troponin T [hs‐cTnT], N‐terminal pro–brain natriuretic peptide) were measured. Results Among the patients in the increased inflammation cohort, the mean age was 59 years, 81% were women, and the mean RA disease duration was 17.9 years. The average increase in hsCRP levels was 36 mg/liter, and this increase was associated with significant reductions in LDL cholesterol, triglycerides, total cholesterol, apolipoprotein (Apo B), and Apo A‐I levels. In the increased inflammation cohort at baseline, 45.6% of patients (47 of 103) had detectable circulating hs‐cTnT, which further increased during inflammation ( P = 0.02). In the decreased inflammation cohort, hs‐cTnT levels remained stable despite a reduction in inflammation over follow‐up. In both cohorts, hs‐cTnT levels were associated with the overall estimated risk of CVD. Conclusion Among RA patients who experienced an increase in inflammation, a significant decrease in routinely measured lipids, including LDL cholesterol, and an increase in markers of subclinical myocardial injury were observed. These findings highlight the divergence in biomarkers of CVD risk and suggest a role in future studies examining the benefit of including hs‐cTnT for CVD risk stratification in RA.